Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists
of VK2809, VK5211, and VK0214 products.
VK2809 and VK0214 are orally available, tissue
and receptor-subtype-selective agonists of the
thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
$VKTX
of VK2809, VK5211, and VK0214 products.
VK2809 and VK0214 are orally available, tissue
and receptor-subtype-selective agonists of the
thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
$VKTX
